Characterization of p53 oligomerization domain mutations isolated from Li–Fraumeni and Li–Fraumeni like family members

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Oncogene

• Publication date

  1998-08-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.onc.1201974PMID 9704930
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family

  1997cited by this paper
• MDM2--arbiter of p53's destruction.

  1997cited by this paper
• Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects

  1997cited by this paper
• p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding

  1997cited by this paper
• Regulation of p53 stability by Mdm2

  1997cited by this paper
• Mdm2 promotes the rapid degradation of p53

  1997cited by this paper
• Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.

  1997cited by this paper
• A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome.

  1996cited by this paper
• DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies.

  1996cited by this paper
• The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target.

  1996cited by this paper
• Structural aspects of the p53 protein in relation to gene evolution: a second look.

  1996cited by this paper
• P53, cell cycle control and apoptosis: Implications for cancer

  1995cited by this paper
• Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.

  1995cited by this paper
• Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6.

  1995cited by this paper
• The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding.

  1995cited by this paper
• Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo.

  1995cited by this paper
• A simple p53 functional assay for screening cell lines, blood, and tumors.

  1995cited by this paper
• Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.

  1994cited by this paper
• p53 domains: structure, oligomerization, and transformation

  1994cited by this paper
• Li-Fraumeni syndrome.

  1994cited by this paper
• The p53-mdm-2 autoregulatory feedback loop.

  1993cited by this paper
• mdm2 expression is induced by wild type p53 activity.

  1993cited by this paper
• Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

  1993cited by this paper
• Definition of a consensus binding site for p53

  1992cited by this paper
• Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli.

  1992cited by this paper
• Abnormal expression of wild type p53 protein in normal cells of a cancer family patient.

  1992cited by this paper
• Regulation of the specific DNA binding function of p53.

  1992cited by this paper
• Apoptosis in interleukin-3-dependent haemopoietic cells. Quantification by two flow cytometric methods.

  1992cited by this paper
• Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

  1990cited by this paper
• Suppression of human colorectal carcinoma cell growth by wild-type p53.

  1990cited by this paper
• Rearrangement of the p53 gene in human osteogenic sarcomas.

  1987cited by this paper
• Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?

  1969cited by this paper

• Tumor suppressor protein p53 governs human trophoblast lineage development.

  2025cites this paper
• In-frame germline TP53 variant impairs p53 oligomerization and predisposes to cancer

  2025influential citation
• TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions

  2025cites this paper
• Correlation of p53 oligomeric status and its subcellular localization in the presence of the AML-associated NPM mutant

  2025cites this paper
• The R337C mutation in the p53 oligomerization domain affects the regulatory domain and its ability to bind response elements: Evidence based on structural and biophysical studies.

  2025cites this paper
• The Advantages of Next-Generation Sequencing Molecular Classification in Endometrial Cancer Diagnosis

  2023cites this paper
• Cytoplasmic localization of Mdm2 in cells expressing mutated NPM is mediated by p53

  2023cites this paper
• Phase separation of p53 induced by its unstructured basic region and prevented by oncogenic mutations in tetramerization domain.

  2022cites this paper
• Mechanistic insight into the destabilization of p53TD tetramer by cancer-related R337H mutation: a molecular dynamics study.

  2022cites this paper
• Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity

  2021cites this paper
• Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities

  2021cites this paper
• TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation

  2021cites this paper
• Gallic Acid Induces S and G2 Phase Arrest and Apoptosis in Human Ovarian Cancer Cells In Vitro

  2021cites this paper
• p53 mediates target gene association with nuclear speckles for amplified RNA expression.

  2021cites this paper
• p53 tetramerization: at the center of the dominant-negative effect of mutant p53

  2020cites this paper
• Role of post-translational modifications in regulation of tumor suppressor p53 function

  2020cites this paper
• Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer

  2019cites this paper
• Regulation of the MDM2‐p53 pathway by the ubiquitin ligase HERC2

  2019cites this paper
• Chapter 2 Quantitative Analysis for p 53 Tetramerization Domain Mutants Reveals a Low Threshold for Tumor Suppressor Inactivation 2

  2019cites this paper
• Ceramide Signaling and p53 Pathways: CHAPTER SEVEN

  2018cites this paper
• Cotranslational protein assembly imposes evolutionary constraints on homomeric proteins

  2018cites this paper
• Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

  2018cites this paper
• Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells

  2018cites this paper
• NEURL4 regulates the transcriptional activity of tumor suppressor protein p53 by modulating its oligomerization

  2017cites this paper
• Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors

  2017cites this paper
• The HERC2 ubiquitin ligase is essential for embryonic development and regulates motor coordination

  2016cites this paper
• p53ness in Human Cancers: An Overview

  2016cites this paper
• Cotranslational assembly imposes evolutionary constraints on homomeric proteins

  2016cites this paper
• Lysines in the tetramerization domain of p53 selectively modulate G1 arrest

  2016cites this paper
• p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis

  2016influential citation
• Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.

  2015cites this paper
• Strategies to identify novel therapeutic targets for oesophageal adenocarcinoma

  2014cites this paper
• The E3 Ubiquitin Protein Ligase HERC2 Modulates the Activity of Tumor Protein p53 by Regulating Its Oligomerization*

  2014cites this paper
• Caracterización funcional de la interacción de la proteïna p53 con la ubiquitina ligasa HERC2

  2014cites this paper
• Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme

  2013cites this paper
• The Nucleolar Protein Myb-binding Protein 1A (MYBBP1A) Enhances p53 Tetramerization and Acetylation in Response to Nucleolar Disruption*

  2013cites this paper
• Estresse oxidativo em indivíduos com síndrome de Li-Fraumeni-like e portadores da mutação germinativa TP53 p.R337H

  2012cites this paper
• The Role of Tumor Protein 53 Mutations in Common Human Cancers and Targeting the Murine Double Minute 2–P53 Interaction for Cancer Therapy

  2012cites this paper
• Quantitative Analysis for p53 Tetramerization Domain Mutants Reveals a Low Threshold for Tumor Suppressor Inactivation

  2012cites this paper
• Towards an understanding of the role of p53 in adrenocortical carcinogenesis.

  2012cites this paper
• The therapeutic potential of RNA interference: novel approaches for cancer treatment.

  2012cites this paper
• Dominant-Negative Features of Mutant TP53 in Germline Carriers Have Limited Impact on Cancer Outcomes

  2011cites this paper
• TP53-Associated Pediatric Malignancies.

  2011cites this paper
• Versatility of PRMT5-induced methylation in growth control and development.

  2011cites this paper
• Occurrence of multipolar mitoses and association with Aurora-A/-B kinases and p53 mutations in aneuploid esophageal carcinoma cells

  2011cites this paper
• Cancer Genes and Genomics Dominant-Negative Features of Mutant TP 53 in Germline Carriers Have Limited Impact on Cancer Outcomes

  2011cites this paper
• Role of p53 in Cell Death and Human Cancers

  2011cites this paper
• limited impact on cancer outcomes.

  2011cites this paper
• p53 activity during adenovirus infection

  2010cites this paper
• p53: The Attractive Tumor Suppressor in the Cancer Research Field

  2010cites this paper
• Analysis of the DNA-binding activity of p53 mutants using functional protein microarrays and its relationship to transcriptional activation

  2010influential citation
• Cancer-associated p53 Tetramerization Domain Mutants

  2010cites this paper
• p53: balancing tumour suppression and implications for the clinic.

  2009cites this paper
• Conformational detection of p53's oligomeric state by FlAsH Fluorescence.

  2009cites this paper
• Modulation of the Oligomerization State of p53 by Differential Binding of Proteins of the S100 Family to p53 Monomers and Tetramers♦

  2009cites this paper
• Posttranslational modifications affect the interaction of S100 proteins with tumor suppressor p53.

  2009cites this paper
• Conformational stability and activity of p73 require a second helix in the tetramerization domain

  2009cites this paper
• Functional characterization of p53β and p53γ, two isoforms of the tumor suppressor p53

  2009cites this paper
• Novel concepts in MDM2 protein regulation

  2009cites this paper
• The do's and don'ts of p53 isoforms

  2009cites this paper
• Regulation of p53 - insights into a complex process

  2009cites this paper
• Functional characterization of p53beta and p53gamma, two isoforms of the tumor suppressor p53.

  2009cites this paper
• Molecular markers and the pathogenesis of adrenocortical cancer.

  2008cites this paper
• Arginine methylation regulates the p53 response

  2008cites this paper
• Use of calix[4]arenes to recover the self-assembly ability of mutated p53 tetramerization domains

  2008cites this paper
• Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53

  2008cites this paper
• Diversity within the master regulatory p53 transcriptional network: Impact of sequence, binding motifs and mutations

  2008influential citation
• Influence of tetramerisation on site-specific post-translational modifications of p53: comparison of human and murine p53 tumour suppressor protein.

  2008cites this paper
• Using peptides to study the interaction between the p53 tetramerization domain and HIV‐1 tat

  2008cites this paper
• The p53 mutation “gradient effect” and its clinical implications

  2007cites this paper
• Functional characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma cell line.

  2007cites this paper
• Regulation of p53 tetramerization and nuclear export by ARC

  2007cites this paper
• The tetramerization domain of p53 is required for efficient BAK oligomerization

  2007cites this paper
• Binding of p53 to the Central Domain of Mdm2 Is Regulated by Phosphorylation*

  2006cites this paper
• Mechanistic insights into maintenance of high p53 acetylation by PTEN.

  2006cites this paper
• Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer.

  2006cites this paper
• The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library

  2005cites this paper
• Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor.

  2005cites this paper
• Disruption of protein–protein interactions: Towards new targets for chemotherapy

  2005cites this paper
• Disruption of an intermonomer salt bridge in the p53 tetramerization domain results in an increased propensity to form amyloid fibrils

  2005cites this paper
• Functional protein microarrays for parallel characterisation of p53 mutants

  2004cites this paper
• Methods for screening tumors for p53 status and therapeutic exploitation

  2003cites this paper
• The gain of function of the p53 mutant Asp281Gly is dependent on its ability to form tetramers.

  2002cites this paper
• A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer

  2002cites this paper
• Tumor-specific mutations in p53: The acid test

  2002cites this paper
• Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines.

  2002cites this paper
• Protein–protein interactions: mechanisms and modification by drugs

  2002cites this paper
• p53 functional assays: detecting p53 mutations in both the germline and in sporadic tumours

  2001cites this paper
• p53 contains a DNA break-binding motif similar to the functional part of BRCT-related region of Rb

  2001cites this paper
• Structure and functionality of a designed p53 dimer.

  2001cites this paper
• The role of tetramerization in p53 function

  2001cites this paper
• Strategies for manipulating the p53 pathway in the treatment of human cancer

  2000cites this paper
• Rare Somatic p53 Mutation Identified in Breast Cancer: A Case Report

  2000cites this paper
• Sigma receptors: recent advances and new clinical potentials.

  2000cites this paper
• Function, oligomerization, and conformation of tumor‐associated p53 proteins with mutated C‐terminus

  2000cites this paper
• Role for the p53 homologue p73 in E2F-1-induced apoptosis

  2000cites this paper
• Strategies for manipulating the p53 pathway in the treatment of human cancer.

  2000cites this paper
• Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay.

  2000cites this paper
• A common E2F-1 and p73 pathway mediates cell death induced by TCR activation

  2000cites this paper
• p73 transcriptional activity increases upon cooperation between its spliced forms

  2000cites this paper